Cryptococcosis in hematology practice
- Authors: Khodunova EE1, Frolova IN1, Parovichnikova EN1, Kravchenko SK1, Galstian GM1, Kostina IÉ1, Mikhaĭlova EA1, Gracheva AN1, Kliasov GA1
-
Affiliations:
- Гематологический научный центр Минздрава России, Москва
- Issue: Vol 85, No 11 (2013)
- Pages: 41-46
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31370
- ID: 31370
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
E E Khodunova
Гематологический научный центр Минздрава России, Москва
I N Frolova
Гематологический научный центр Минздрава России, Москва
E N Parovichnikova
Гематологический научный центр Минздрава России, Москва
S K Kravchenko
Гематологический научный центр Минздрава России, Москва
G M Galstian
Гематологический научный центр Минздрава России, Москва
I É Kostina
Гематологический научный центр Минздрава России, Москва
E A Mikhaĭlova
Гематологический научный центр Минздрава России, Москва
A N Gracheva
Гематологический научный центр Минздрава России, Москва
G A Kliasov
Гематологический научный центр Минздрава России, Москва
Email: klias@blood.ru
125167 Москва, Новый Зыковский пр-д, д. 4
References
- Hajjeh R.A., Conn L.A., Stephens D.S. et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J Infect Dis 1999; 179 (2): 449-454.
- Sepkowitz K.A. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis 2002; 34 (8): 1098-1107.
- Subramanian S., Mathai D. Clinical manifestations and management of cryptococcal infection. J Postgrad Med 2005; 51 Suppl 1: 21- 26.
- Pappas P.G., Perfect J.R., Cloud G.A. et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001; 33 (5): 690-699.
- Kerkering T.M., Duma R.J., Shadomy S. The evolution of pulmonary cryptococcosis: clinical implications from a study of 41 patients with and without compromising host factors. Ann Intern Med 1981; 94: 611-616.
- Perfect J.R. Cryptococcosis. In: Systemic Fungal Infections: Diagnosis and treatment II. Infect Dis Clin North Am 1989; 3: 77-102.
- Loyse A., Wainwright H., Jarvis J.N. et al. Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. AIDS 2010; 24 (3): 405-410.
- Hansen J., Slechta E.S., Gates-Hollingsworth M.A. et al. Large-scale evaluation of the immuno-mycologics lateral flow and enzyme-linked immunoassays for detection of cryptococcal antigen in serum and cerebrospinal fluid. Clin Vaccine Immunol 2013; 20 (1): 52-55.
- Binnicker M.J., Jespersen D.J., Bestrom J.E., Rollins L.O. Comparison of four assays for the detection of cryptococcal antigen. Clin Vaccine Immunol 2012; 19 (12): 1988-1990.
- De Pauw B., Walsh T.J., Donnelly J.P. et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46 (12): 1813-1821.
- Kontoyiannis D.P., Peitsch W.K., Reddy B.T. et al. Cryptococcosis in patients with cancer. Clin Infect Dis 2001; 32 (11): 145-150.
- Pagano L., Fianchi L., Caramatti C. et al. Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection. Haematologica 2004; 89 (7): 852-856.
- Vigouroux S., Morin O., Milpied N. et al. Cryptococcus neoformans infection in hematologic malignancies. Rev Med Interne 2000; 21 (11): 955-960.
- Caira M., Trecarichi E.M., Tumbarello M. et al. Uncommon yeast infections in hematological patients: from diagnosis to treatment. Expert Rev Anti Infect Ther 2011; 9 (11): 1067-1075.
- Perfect J.R., Dismukes W.E., Dromer F. et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010; 50 (3): 291-322.
- Vermes A., Guchelaar H.J., Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000; 46 (2): 171-179.
- Pfaller M.A., Messer S.A., Boyken L. et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). Clin Microbiol 2005; 43 (5): 2163-2167.
- Johnson L.B., Kauffman C.A. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36 (5): 630-637.
- Loyse A., Wilson D., Meintjes G. et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2012; 54 (1): 121-128.